Roche, Novartis, Lilly, J&J: Earnings Call Roundup For Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
In a recurring feature, PharmAsia News monitors major earnings calls to report on new trends in emerging market strategies.
You may also be interested in...
Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan
Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan
Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics
TOKYO - Nichi-Iko has upped its capability to bring biosimilars to the Japanese market, buying a 33 percent stake in South Korean biosimilar firm Aprogen, giving the Japanese generics maker exclusive rights to Aprogen products in Japan